← back to database
ExSight Ventures provides funding for early-stage ophthalmology companies developing vision-saving diagnostics and treatments. It leverages a team of retinal surgeons and investment professionals to assess science, clinical impact, and capital efficiency. The firm targets biotechnology, medical devices, pharmaceuticals, and ophthalmic software solutions across pre-seed to Series B. As a focused life sciences VC, it differentiates by deep domain expertise and a network that accelerates clinical pathways and product validation.
Primary stage
Hardware / software
B2B / B2C
Investment focus
Investment style
Specialist
Data last enriched
Aug 14, 2026
Investing team
- James C. MurrayPartner
- Michael NissenPartner
- Firas M. RahhalPartner
Notable investments
ELIOS Vision, Re-Vana Therapeutics, Horizon Surgical Systems, DTx Pharma, Trefoil Therapeutics, Qura, 2C Tech Corporation, ONL Therapeutics, LensGen, Valitor Bio